GlassScriptPhysician profile
Laura Lee Blechner
NPI 1740490663
$4,124.04
in general payments reported to CMS, 2019-2025
24 companies · $896 in 2025
The $896 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $1,054 · 2023: $935 · 2024: $1,016 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,846.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $931.59 | 2022-2025 | Trelegy Ellipta |
| Abbvie INC. | $566.30 | 2021-2025 | |
| Novo Nordisk INC | $438.98 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $307.81 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $298.84 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $218.66 | 2023-2025 | Cologuard Collection Kit |
| Philips North America LLC | $181.15 | 2022-2024 | (Ak6) Vest Therapy |
| Lilly USA, LLC | $171.99 | 2021-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.75 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $129.30 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $114.48 | 2024-2025 | Zenpep |
| Corcept Therapeutics | $113.10 | 2023-2024 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $108.54 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $73.70 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.81 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $47.58 | 2022-2024 | Yupelri |
| Pfizer INC. | $44.61 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.49 | 2025 | Relistor, Xifaxan |
| Teva Pharmaceuticals USA, INC. | $36.71 | 2021 | |
| Smith+Nephew, INC. | $33.45 | 2024 | Collagenase Santyl |
| Amgen INC. | $27.11 | 2025 | Repatha |
| Biohaven Pharmaceuticals, INC. | $24.71 | 2021 | |
| Amarin Pharma, INC. | $20.52 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.86 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Blechner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.